Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ01024 Combined With Ruxolitinib in Myelofibrosis
NCT06909136Phase 2Active, not recruiting
- Sponsor
- Suzhou Junjing BioSciences
- Start
- Jul 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WJ01024 in myelofibrosis (MF), sponsored by Suzhou Junjing BioSciences. Started Jul 2025; status: active, not recruiting.
02
Drugs
WJ01024
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06909136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06909136.